Risk Management Guidance Suggests Advisory Cmte Review For RiskMAPs
Executive Summary
FDA recommends that advisory committees weigh in on whether a risk minimization action plan is appropriate for a particular drug
You may also be interested in...
Waking Up To REMS: Sponsors Should Test Risk Management In Phase III
With Risk Evaluation and Mitigation Strategies supplanting Risk Minimization Action Plans, drug sponsors would be well served to begin preparing for negotiations over risk management plans during product development
Waking Up To REMS: Sponsors Should Test Risk Management In Phase III
With Risk Evaluation and Mitigation Strategies supplanting Risk Minimization Action Plans, drug sponsors would be well served to begin preparing for negotiations over risk management plans during product development
REMS Take Effect; FDA Identifies 16 Products With RiskMAPs That Qualify
Manufacturers of approved products whose marketing conditions qualify for a Risk Evaluation and Mitigation Strategy will have to develop a timeline for the assessment of their risk management efforts by September 21